BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med. 2013;126:730.e9-730.e17. [PMID: 23885678 DOI: 10.1016/j.amjmed.2013.02.016] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Desai RJ, Solomon DH. Use of large healthcare databases for rheumatology clinical research. Curr Opin Rheumatol 2017;29:138-43. [PMID: 27984323 DOI: 10.1097/BOR.0000000000000363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Day AL, Singh JA. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? Drugs Aging 2019;36:493-510. [PMID: 30953327 DOI: 10.1007/s40266-019-00653-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Soh MC, Nelson-Piercy C, Westgren M, McCowan L, Pasupathy D. Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus? Lupus 2017;26:1351-67. [PMID: 28728509 DOI: 10.1177/0961203317719146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lima-Martínez MM, Campo E, Salazar J, Paoli M, Maldonado I, Acosta C, Rodney M, Contreras M, Cabrera-Rego JO, Iacobellis G. Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies. Arthritis. 2014;2014:782850. [PMID: 25574390 DOI: 10.1155/2014/782850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
5 Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505-522. [PMID: 30065258 DOI: 10.1038/s41569-018-0064-2] [Cited by in Crossref: 552] [Cited by in F6Publishing: 436] [Article Influence: 276.0] [Reference Citation Analysis]
6 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482-9c. [PMID: 25433021 DOI: 10.1093/eurheartj/ehu403] [Cited by in Crossref: 190] [Cited by in F6Publishing: 131] [Article Influence: 27.1] [Reference Citation Analysis]
7 Dhillon N, Liang K. Prevention of stroke in rheumatoid arthritis. Curr Treat Options Neurol 2015;17:356. [PMID: 25981388 DOI: 10.1007/s11940-015-0356-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Parikh NS, Merkler AE, Iadecola C. Inflammation, Autoimmunity, Infection, and Stroke: Epidemiology and Lessons From Therapeutic Intervention. Stroke 2020;51:711-8. [PMID: 32078460 DOI: 10.1161/STROKEAHA.119.024157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 19.0] [Reference Citation Analysis]
9 Mason JC. Cytoprotective pathways in the vascular endothelium. Do they represent a viable therapeutic target? Vascul Pharmacol 2016;86:41-52. [PMID: 27520362 DOI: 10.1016/j.vph.2016.08.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
10 England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018;361:k1036. [PMID: 29685876 DOI: 10.1136/bmj.k1036] [Cited by in Crossref: 99] [Cited by in F6Publishing: 68] [Article Influence: 33.0] [Reference Citation Analysis]
11 Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opin Drug Saf 2016;15:55-61. [PMID: 27924645 DOI: 10.1080/14740338.2016.1218469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
12 Yao W, Tao C, Zou J, Zheng H, Zhu J, Zhu Z, Zhu J, Liu L, Li F, Song X. Flexible two-layer dissolving and safing microneedle transdermal of neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis. International Journal of Pharmaceutics 2019;563:91-100. [DOI: 10.1016/j.ijpharm.2019.03.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
13 Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res (Hoboken) 2015;67:457-66. [PMID: 25302481 DOI: 10.1002/acr.22483] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
14 Guo S, Messmer-Blust AF, Wu J, Song X, Philbrick MJ, Shie JL, Rana JS, Li J. Role of A20 in cIAP-2 protection against tumor necrosis factor α (TNF-α)-mediated apoptosis in endothelial cells. Int J Mol Sci 2014;15:3816-33. [PMID: 24595242 DOI: 10.3390/ijms15033816] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
15 Desai RJ, Solomon DH, Weinblatt ME, Shadick N, Kim SC. An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Res Ther 2015;17:83. [PMID: 25880932 DOI: 10.1186/s13075-015-0599-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol 2016;12:594-604. [DOI: 10.1038/nrneurol.2016.125] [Cited by in Crossref: 114] [Cited by in F6Publishing: 95] [Article Influence: 22.8] [Reference Citation Analysis]
17 Carvalho AV, Romiti R, Souza CD, Paschoal RS, Milman LM, Meneghello LP. Psoriasis comorbidities: complications and benefits of immunobiological treatment. An Bras Dermatol 2016;91:781-9. [PMID: 28099601 DOI: 10.1590/abd1806-4841.20165080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
18 Ozen G, Pedro S, Michaud K. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. J Rheumatol 2021;48:648-55. [PMID: 32801134 DOI: 10.3899/jrheum.200265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
19 Lee JS, Chapman MJ, Piraino P, Lamerz J, Schindler T, Cutler P, Dernick G. Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab. Proteomics Clin Appl 2016;10:183-94. [PMID: 26201085 DOI: 10.1002/prca.201500036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis 2017;76:1583-90. [PMID: 28483768 DOI: 10.1136/annrheumdis-2017-211209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
21 Legge A, Hanly JG. Managing premature atherosclerosis in patients with chronic inflammatory diseases. CMAJ 2018;190:E430-9. [PMID: 29632038 DOI: 10.1503/cmaj.170776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chodara AM, Wattiaux A, Bartels CM. Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches. Curr Rheumatol Rep 2017;19:16. [PMID: 28361332 DOI: 10.1007/s11926-017-0643-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
23 Gómez-Bañuelos E, Martín-Márquez BT, Martínez-García EA, Figueroa-Sanchez M, Nuñez-Atahualpa L, Rocha-Muñoz AD, Sánchez-Hernández PE, Navarro-Hernandez RE, Madrigal-Ruiz PM, Saldaña-Millan AA, Duran-Barragan S, Gonzalez-Lopez L, Gamez-Nava JI, Vázquez-Del Mercado M. Low levels of CD36 in peripheral blood monocytes in subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study in a Mexican population. Biomed Res Int 2014;2014:736786. [PMID: 25006585 DOI: 10.1155/2014/736786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 2014;41:2129-36. [PMID: 25086079 DOI: 10.3899/jrheum.131464] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kang EH, Jin Y, Brill G, Lewey J, Patorno E, Desai RJ, Kim SC. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. J Am Heart Assoc 2018;7:e007393. [PMID: 29367417 DOI: 10.1161/JAHA.117.007393] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
26 Karpouzas GA, Bui VL, Ronda N, Hollan I, Ormseth SR. Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. Expert Rev Clin Immunol 2021;17:355-74. [PMID: 33673792 DOI: 10.1080/1744666X.2021.1899809] [Reference Citation Analysis]
27 Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther 2018;20:171. [PMID: 30086795 DOI: 10.1186/s13075-018-1669-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 15.7] [Reference Citation Analysis]
28 Agca R, Heslinga SC, Rollefstad S, Heslinga M, Mcinnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2016;76:17-28. [DOI: 10.1136/annrheumdis-2016-209775] [Cited by in Crossref: 512] [Cited by in F6Publishing: 334] [Article Influence: 102.4] [Reference Citation Analysis]
29 Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L; ARTIS Study Group. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014;16:R127. [PMID: 24941916 DOI: 10.1186/ar4584] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
30 Krüger K. [Treatment of cardiovascular risk factors]. Z Rheumatol 2016;75:173-80; quiz 181-2. [PMID: 26924198 DOI: 10.1007/s00393-016-0064-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
31 Li H, Liu H. Investigating the Mechanisms of Action of Depside Salt from Salvia miltiorrhiza Using Bioinformatic Analysis. Evid Based Complement Alternat Med 2017;2017:5671860. [PMID: 29348768 DOI: 10.1155/2017/5671860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Zha AM, Di Napoli M, Behrouz R. Prevention of Stroke in Rheumatoid Arthritis. Curr Neurol Neurosci Rep 2015;15:77. [PMID: 26486791 DOI: 10.1007/s11910-015-0600-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
33 Atzeni F, Talotta R, Nucera V, Marino F, Gerratana E, Sangari D, Masala IF, Sarzi-puttini P. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Review of Clinical Immunology 2018;14:945-56. [DOI: 10.1080/1744666x.2018.1504678] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol 2016;152:164-72. [PMID: 26510126 DOI: 10.1001/jamadermatol.2015.3029] [Cited by in Crossref: 82] [Cited by in F6Publishing: 50] [Article Influence: 16.4] [Reference Citation Analysis]
35 Boyce EG, Vyas D, Rogan EL, Valle-Oseguera CS, O'Dell KM. Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies. Patient Relat Outcome Meas 2016;7:1-12. [PMID: 26834501 DOI: 10.2147/PROM.S62879] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 Tang CH, Yu F, Huang CY, Chen DY. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan. Int J Rheum Dis 2019;22:1544-52. [PMID: 31240863 DOI: 10.1111/1756-185X.13611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-randone S, Matucci-cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 2016;45:519-32. [DOI: 10.1016/j.semarthrit.2015.10.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
38 Daniel CM, Davila L, Makris UE, Mayo H, Caplan L, Davis L, Solow EB. Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review. ACR Open Rheumatol 2020;2:525-32. [PMID: 32869533 DOI: 10.1002/acr2.11170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lai HY, Chang HT, Lee YL, Hwang SJ. Association between inflammatory markers and frailty in institutionalized older men. Maturitas 2014;79:329-33. [PMID: 25132319 DOI: 10.1016/j.maturitas.2014.07.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
40 Li C, Wang XR, Ji HJ, Zhang XY, Li XF, Wang LZ, Wang CH, Wang YF, Yang R, Wang GC, Lu X, Zhu P, Chen LN, Jin HT, Liu JT, Liu XY, Sun L, Chen HY, Wei P, Wang JX, Cui LF, Shu R, Liu BL, Zhang ZL, Li GT, Li ZB, Yang J, Li JF, Jia B, Zhang FX, Tao JM, Han SL, Lin JY, Wei MQ, Liu XM, Ke D, Hu SX, Ye C, Yang XY, Li H, Huang CB, Gao M, Lai B, Li XF, Song LJ, Wang Y, Wang XY, Tang YD, Su Y, Mu R, Li ZG. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol 2017;36:1023-9. [PMID: 28342151 DOI: 10.1007/s10067-017-3596-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2020;72:561-76. [PMID: 30875456 DOI: 10.1002/acr.23875] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 37.0] [Reference Citation Analysis]
42 Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol 2017;69:1154-64. [PMID: 28245350 DOI: 10.1002/art.40084] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 24.3] [Reference Citation Analysis]
43 Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. [PMID: 25561362 DOI: 10.1136/annrheumdis-2014-206624] [Cited by in Crossref: 428] [Cited by in F6Publishing: 320] [Article Influence: 71.3] [Reference Citation Analysis]
44 Curtis JR, Xie F, Chen L, Saag KG, Yun H, Muntner P. Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 2018;77:386-92. [PMID: 29269418 DOI: 10.1136/annrheumdis-2017-211727] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
45 Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, Dixon WG, Hyrich KL; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:654-660. [PMID: 28073800 DOI: 10.1136/annrheumdis-2016-209784] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
46 Shah NR, Mahmoudi M. The role of DNA damage and repair in atherosclerosis: A review. Journal of Molecular and Cellular Cardiology 2015;86:147-57. [DOI: 10.1016/j.yjmcc.2015.07.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
47 Desai RJ, Solomon DH, Schneeweiss S, Danaei G, Liao KP, Kim SC. Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology 2016;27:414-22. [PMID: 26808597 DOI: 10.1097/EDE.0000000000000446] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
48 Chen DY, Yu F, Tuan LW, Tang CH. Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan. Front Pharmacol 2019;10:1214. [PMID: 31695611 DOI: 10.3389/fphar.2019.01214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Sen D, González-Mayda M, Brasington RD. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2014;40:27-49. [PMID: 24268008 DOI: 10.1016/j.rdc.2013.10.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
50 Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol 2014;15:45-50. [PMID: 24281789 DOI: 10.1007/s40257-013-0052-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
51 Chaabo K, Kirkham B. Rheumatoid Arthritis - Anti-TNF. Int Immunopharmacol 2015;27:180-4. [PMID: 25962818 DOI: 10.1016/j.intimp.2015.04.051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
52 Karpouzas GA, Ormseth SR, Hernandez E, Budoff MJ. Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk Lesions. Arthritis Rheumatol 2020;72:1467-75. [DOI: 10.1002/art.41293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
53 Reverri EJ, Morrissey BM, Cross CE, Steinberg FM. Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radical Biology and Medicine 2014;76:261-77. [DOI: 10.1016/j.freeradbiomed.2014.08.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
54 Ljung L, Rantapää-dahlqvist S, Jacobsson LTH, Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis 2016;75:2087-94. [DOI: 10.1136/annrheumdis-2015-208995] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
55 Kang EH, Liao KP, Kim SC. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0752-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]